Esperion appoints Stephen Rocamboli to board; Dr. Mark McGovern resigns

Esperion Therapeutics, Inc.

Mark McGovern resigned from board effective April 28, 2022; no disagreement cited.
Stephen Rocamboli elected to fill vacancy; will serve on Audit Committee.
Rocamboli is CEO of Perla Therapeutics, with prior life science board and executive roles.
Esperion expects topline readout of CLEAR Outcomes trial in Q1 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark E. McGovern

Director

ESPR · Esperion Therapeutics, Inc.

Effective: 2022-04-28
Successor: Stephen Rocamboli
Filed: April 28, 2022, 7:59 PM ET

On April 28, 2022, Mark E. McGovern, M.D. notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) of his decision to resign from the Board, effective immediately.

Appointed

Stephen Rocamboli

Director

ESPR · Esperion Therapeutics, Inc.

Effective: 2022-04-28
Filed: April 28, 2022, 7:59 PM ET

On April 28, 2022, the Board elected Stephen Rocamboli to fill the newly created vacancy on the Board resulting from Dr. McGovern’s resignation from the Board, effective April 28, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark E. McGovern resigned as Director at Esperion Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 28, 2022, Mark E. McGovern, M.D. notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) of his decision to resign from the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Rocamboli was elected as Director at Esperion Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On April 28, 2022, the Board elected Stephen Rocamboli to fill the newly created vacancy on the Board resulting from Dr. McGovern’s resignation from the Board, effective April 28, 2022.

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-011120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.